Blog Archives - Myriad RBM
  • Subscribe to our Blog

    Receive excerpts from our latest posts via email.

  • Categories


    Identifying Novel Biomarkers for Cardiovascular Events or Death in People With Dysglycemia

    An international team of researchers used Myriad RBM’s Multi-Analyte Profile (MAP) technology to identify a pattern of cardiometabolic biomarkers that appears to predict cardiovascular outcomes in patients with dysglycemia. This data, the latest publication stemming from the landmark Outcome Reduction with Initial Glargine Intervention (ORIGIN) trial, holds great promise for prognosis and treatment of patients […]

    » Read this post

    Use of biomarkers to guide immunotherapy drug development

    VentiRx, the developers of motolimod, a TLR8 agonist, have published preclinical and clinical results that indicate effective immune system stimulation in human whole blood cultures, non-human primates, healthy subjects, and late-stage cancer patients. Immune system stimulation in all of these settings is dose-dependent, characterized by similar biomarkers, and consistent with stimulation via the TLR8 pathway. […]

    » Read this post

    New serum biomarkers found to be associated with the progression of chronic kidney disease in patients with type 2 diabetes

    European researchers identified a panel of 14 serum biomarkers that improved the prediction of progression of chronic kidney disease (CKD) in patients with type 2 diabetes. Using Myriad RBM’s services, as well as other protein detection methods, the researchers measured a total of 207 serum proteins and successfully identified several new associations of biomarkers indicative […]

    » Read this post

    Blood-based biomarkers show promise as an early diagnostic tool for RA-ILD

    Researchers at Brigham and Women’s Hospital, Harvard Medical School demonstrate the utility of a blood-based panel for identifying Interstitial Lung Disease (ILD) in Rheumatoid Arthritis (RA) patients. The comorbidity of RA-ILD is prevalent and is associated with negative patient outcomes: ILD is the second leading cause of death in patients with RA. When combined with […]

    » Read this post

    Prototypic modified risk tobacco product reduces cigarette smoke induced inflammation and COPD symptoms in mice

    Researchers at Philip Morris used Myriad RBM’s RodentMAP (Multi-Analyte Profiling) immunoassay service and other histological and functional assessments to demonstrate that prototypic modified risk tobacco product (pMRTP) aerosol stops emphysema progression and eliminates most inflammatory processes when compared to mice exposed to cigarette smoke. The pMRTP investigated is based on a distillation technology with a […]

    » Read this post

    Pharmacodynamic biomarkers for Apremilast treatment in psoriatic arthritis

    A new paper from Peter Schafer, et al, of Celgene shows how biomarkers can be used to monitor treatment response in an inflammatory disease setting. The early timepoints show a dose-dependent biomarker response while the later timepoints show a more normalized response, possibly correlated with reduced disease severity. Read Paper »

    » Read this post

    ENRAGE: A Novel Inflammatory Marker for Incident Coronary Heart Disease

    This recent paper in the Arteriosclerosis, Thrombosis and Vascular Biology Journal of the American Heart Association describes an interesting prospective study of 839 coronary heart disease (CHD)-free individuals who were followed for about 10 years with blood based biomarker testing. As the mean age at the beginning of the study was 73 years, 99 individuals […]

    » Read this post

    Blood-based proteins are crucial to the development of biomarker tests aimed at improving the diagnosis and treatment of psychiatric disorders

    A recent review of studies measuring proteins in blood serum/plasma illustrates the systemic nature of disease-related changes in patients with schizophrenia, major depressive and bipolar disorders. The collection of studies examined, including many that utilized Myriad RBM’s services, underscores the importance of including analysis of these peripheral proteins in the development of validated biomarker tests […]

    » Read this post

    Biomarker signatures predict clinical outcomes in metastatic colorectal cancer (mCRC) patients treated with chemotherapy and cediranib

    Researchers sought to explore biomarkers in pre- and on- treatment mCRC patients receiving chemotherapy with and without cediranib, in order to identify patient subgroups who may benefit from the combination cediranib therapy.

    » Read this post

    Vitamin D Binding Protein in serum demonstrates utility as a biomarker of Alzheimer’s disease

    Researchers at the University of Texas Health Science Center, San Antonio used a Multiple Indicators Multiple Causes (MIMIC) approach to evaluate the correlation between serum Vitamin D binding protein (VDBP) levels and cognitive performance in Alzheimer’s patients. While further studies are needed, this research suggests that increased levels of serum VDBP may be helpful in […]

    » Read this post